Last reviewed · How we verify
Udenafil 100 mg
At a glance
| Generic name | Udenafil 100 mg |
|---|---|
| Also known as | WC3043 |
| Sponsor | Warner Chilcott |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With Sildenafil
- Treatment of Erectile Dysfunction II (PHASE3)
- Treatment of Erectile Dysfunction - Long Term Safety and Efficacy (PHASE3)
- Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure (PHASE3)
- A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT] (PHASE3)
- A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF] (PHASE3)
- Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon (PHASE2, PHASE3)
- Treatment of Erectile Dysfunction I (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Udenafil 100 mg CI brief — competitive landscape report
- Udenafil 100 mg updates RSS · CI watch RSS
- Warner Chilcott portfolio CI